Stock ALKERMES
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company ALKERMES Nasdaq

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for ALKERMES
06-17 TD Cowen Initiates Alkermes at Buy With $34 Price Target MT
06-11 Transcript : Alkermes plc Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 10:40 AM

Business Summary

Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Sales per Business

USD in Million2022Weight2023Weight Delta
Product
55.3 %
778 69.9 % 920 55.3 % +18.32%
Manufacturing and Royalty
44.7 %
332 29.9 % 743 44.7 % +123.92%
Research and Development
0.0 %
0 0.0 % 0 0.0 % -92.69%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
89.7 %
932 83.8 % 1,492 89.7 % +60.08%
Rest of World
10.2 %
178 16.0 % 170 10.2 % -4.32%
Ireland
0.1 %
2 0.2 % 1 0.1 % -35.54%

Managers

Managers TitleAgeSince
Richard Pops CEO
 Chief Executive Officer 62 91-01-31
Blair Jackson DFI
 Director of Finance/CFO 51 98-12-31
Shane Cooke PSD
 President 61 11-08-31
Sondra Smyrnios CTO
 Chief Tech/Sci/R&D Officer - 19-06-30
Craig Hopkinson CTO
 Chief Tech/Sci/R&D Officer 56 17-05-29
Thomas Harvey CTO
 Chief Tech/Sci/R&D Officer - 04-12-31
Kanchan Relwani CTO
 Chief Tech/Sci/R&D Officer - 16-12-31
Declan O’Connor COO
 Chief Operating Officer - 11-08-31
David Gaffin CMP
 Compliance Officer 52 16-04-30
Markus Haeberlein CTO
 Chief Tech/Sci/R&D Officer - -

Members of the board

Members of the board TitleAgeSince
Richard Pops CEO
 Chief Executive Officer 62 91-01-31
Nancy Snyderman BRD
 Director/Board Member 72 16-05-25
Brian McKeon BRD
 Director/Board Member 61 20-12-09
Dave Daglio BRD
 Director/Board Member - 20-12-09
Shane Cooke BRD
 Director/Board Member 61 11-08-31
Andy Wilson BRD
 Director/Board Member 65 19-09-11
Cato Laurencin BRD
 Director/Board Member 65 21-11-17
Christopher Wright BRD
 Director/Board Member 58 22-05-23
Richard Gaynor BRD
 Director/Board Member 74 19-09-11
Emily Alva BRD
 Director/Board Member 49 21-05-17

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 175,771,015 167,110,486 ( 95.07 %) 6,549,704 ( 3.726 %) 95.07 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
16.16 %
27,347,292 16.16 % 640 M $
Vanguard Fiduciary Trust Co.
11.91 %
20,161,180 11.91 % 472 M $
Wellington Management Co. LLP
8.801 %
14,892,360 8.801 % 348 M $
STATE STREET CORPORATION
5.321 %
9,003,913 5.321 % 211 M $
T. Rowe Price International Ltd.
4.920 %
8,326,256 4.920 % 195 M $
RTW Investments LP
3.578 %
6,054,280 3.578 % 142 M $
Renaissance Technologies LLC
3.479 %
5,887,151 3.479 % 138 M $
Pacer Advisors, Inc.
2.528 %
4,278,563 2.528 % 100 M $
Geode Capital Management LLC
2.212 %
3,742,771 2.212 % 88 M $
Deep Track Capital LP
2.068 %
3,500,000 2.068 % 82 M $

Company contact information

Alkermes Plc

Connaught House 1 Burlington Road

4, Dublin

+

http://www.alkermes.com
address ALKERMES

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
LONZA GROUP AG Stock Lonza Group AG
+38.65% 39.36B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-8.62% 38.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+26.95% 30.74B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+10.74% 25.92B
CELLTRION, INC. Stock Celltrion, Inc.
-13.50% 26.03B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.87% 14.13B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+34.36% 12.73B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.14% 11.29B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-12.61% 10.64B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALKS Stock
  4. Stock
  5. Company ALKERMES